The role of T lymphocytes in cancer patients undergoing immunotherapy with autologous dendritic cells

Clinical Medicine Insights: Oncology

Volumn 5, Issue , 2011, Pages 107-115

  Rodrigues, Cláudia M ^a   Matias, Bruna F ^a   Murta, Eddie F C ^a   Michelin, Márcia A ^a  

^a FEDERAL UNIVERSITY OF TRIÂNGULO MINEIRO   (Brazil)

Author keywords

Cancer; Cytokines; Dendritic cells; Immunotherapy; T cells

Indexed keywords

CYTOKINE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL POPULATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG SAFETY; FEMALE; FLOW CYTOMETRY; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; MALE; MELANOMA; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; UTERINE CERVIX CANCER; VAGINA CANCER; VITILIGO;

EID: 79958034692     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S6927     Document Type: Article

References (51)

1. Hart IR. Biology of cancer. Medicine. 2004;32(3):1-5.
2. Zitvogel L, Apetoh L, Ghiringhelli F, André F, Tesniere A, Kroemer G. The anticancer immune response: indispensable for therapeutic success? The Journal of Clinical Investigation. 2008;118(6):1992-2001.
3. Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nature Reviews Cancer. 2006;6:24-37.
4. Degli-Esposti MA, Smyth MJ. Close encounters of different kinds:dendritic cells and NK cells take centre stage. Nature Reviews Immunology. 2005; 5:112-24.
5. Johansson M, Denardo DG, Coussens LM. Polarized immune responsesdifferentially regulate cancer development. Immunological Reviews. 2008; 222:145-54.
6. Yewdell JW, Norbury CC, Bennink JR. Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8 T cell responses to infectious agents, tumours, transplants, and vaccines. Advances in Immunology. 1999;73:1-77.
7. Guermonprez P, Saveanu L, Kleijmeer M, Davoust J, Van Endert P, Amigorena S. ER-phagosome fusion defines an MHC class I cross- Presentation compartment in dendritic cells. Nature. 2003;425:397-402.
8. McDonnell AM, Robinson BWS, Currie AJ. Tumor antigen cross presentation and the dendritic where it all begins? Clinical and Developmental Immunology. 2010;2010, Article ID 539519, 9 pages.
9. Topalian SL, Gonzales MI, Parkhurst M, et al. Melanoma-specific CD4 T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. Journal Experimental Medicine. 1996;183:1965-197.
10. Chaux P, Vantomme V, Stroobant V. Identifi{ligature}cation of MAGE-3 epitopes presented by HLA-DR molecules to CD41 T lymphocytes. The Journal of Experimental Medicine. 1999;189(5):767-77.
11. Gabrilovich D. Mechanisms and functional significance of tumor-induced dendritic-cell defects. Nature Reviews Immunology. 2004;4:941-52.
12. Bella SD, Gennaro M, Vaccari M, et al. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. British Journal of Cancer. 2003;89:1463-72.
13. Röllig C, Schmidt C, Bornhäuser M, Ehninger G, Schmitz M, Auffermann- Gretzinger S. Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells. Journal of Immunotherapy. 2011;34(1):100-6.
14. Santin AD, Bellone S, Palmieri M, et al. HPV 16/18-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecologic Oncologic. 2006;100:409-78.
15. Matsuda K, Tsunoda T, Tanaka H. Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide-pulsed dendritic cells. Cancer Immunology Immunotherapy. 2004;53:609-16.
16. Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. Journal of Immunotherapy with Emphasis on Tumor Immunology. 1996;19(1):81-4.
17. Jacobs JF, Aarntzen EH, Sibelt LA, et al. Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients. Cancer Immunology Immunotherapy. 2009;58(1):145-51.
18. Fong L, Brockstedt D, Benike C, Wu L, Engleman EG. Dendritic cells injected via different routes induce immunity in cancer patients. The JournalImmunology. 2001;166:4254-9.
19. Mumberg D, Monach PA, Wanderling S, et al. CD4 T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-g. Proceedings of the National Academy of Sciences of the United States of America. 1999;96:8633-8.
20. Naylor MS, Stamp GWH, Foulkes WD, Eccles D, Balkwill FR. Tumor necrosis factor and its receptors in human ovarian cancer potential role in disease progression. Journal Clinical Investigation. 1993;91:2194-206.
21. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?Lancet. 2001;357:539-45.
22. Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine and Growth Factor Reviews. 2002;13:135-41.
23. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM. Development of Th1 CD4+ T cells through IL-12 produced by Listeriainduced macrophages. Science. 1993;260:547-9.
24. Dorman SE, Holland SM. Interferon-g and interleukin-12 pathway defects and human disease. Cytokine and Growth Factor Reviews. 2000;11: 321-33.
25. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with 1 immunoregulatory functions in the generation of T-helper cells type and cytotoxic lymphocytes. Blood. 1994;84:4008-27.
26. Chang HD, Helbig C, Tykocinski L, et al. Expression of IL-10 in Th memory lymphocytes is conditional on IL-12 or IL-4, unless the IL-10 gene is imprinted by GATA-3. European Journal of Immunology. 2007;37(3): 807-17.
27. Bingisser R, Speich R, Zollinger A, Russi E, Frei K. Interleukin-10 secretion by alveolar macrophages and monocytes in sarcoidosis. Respiration. 2000;67:280-6.
28. Groux H, Bigler M, de Vries JE, Roncarolo MG. Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. The Journal of Immunology. 1998;160(7):3188-93.
29. Trinchieri G. Interleukin-10 production by effector T cells: Th1 cells show self control. The Journal of Experimental Medicine. 2007;204(2):239-43.
30. Rutz S, Janke M, Kassner N, Hohnstein T, Krueger M, Scheffold A. notch regulates IL-10 production by T helper 1 cells. Proceeding of the National Academy of Sciences of the United States of America. 2008;105(9): 3497-502.
31. Adris S, Klein S, Jasnis M, et al. IL-10 expression by CT26 colon carcinoma cells inhibits their malignant phenotype and induces a T cell-mediated tumor rejection in the context of a systemic Th2 response. Gene Therapy. 1999;6:1705-12.
32. Fujii S, Shimizu K, Shimizu T, Lotze MT. Interleukin-10 promotes the maintenance of antitumor CD8 function in situ. Blood. 2001;98(7):2143-51.
33. Saraiva M, Christensen JR, Veldhoen M, Murphy TL, Murphy KM, O'Garral A. Interleukin-10 Production by Th1 cells requires interleukin- 12-Induced STAT4 transcription factor and ERK MAP kinase activation by high antigen dose. Immunity. 2009;31:209-19.
34. Fehniger TA, Cooper MA, Caligiuri MA. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine and Growth Factor Reviews. 2002;13: 169-83.
35. Avigan D, Vasir B, Gong J, et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clinical Cancer Research. 2004;15(10):4699-708.
36. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood. 2000;96(9):3102-8.
37. Haas W, Pereira P, Tonegawa S. Gamma/delta cells. Annual Review of Immunology. 1993;11:637-85.
38. Kaufmann SH. γδ and other unconventional T lymphocytes: what do they see and what do they do? Proceeding of the National Academy of Sciences of the United States of America. 1996;93:2272-2279.
39. Déchanet J, Merville P, Lim A. Implication of γδ T cells in the human immune response to cytomegalovirus. The Journal of Clinical Investigation. 1999;103:1437-49.
40. Godfrey D I, Hammond KJL, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunology Today. 2000;21(11):573-83.
41. MacDonald HR. Development and selection of NKT cells. Current Opinion in Immunology. 2002;14:250-4.
42. Terabe M, Matsui S, Noben-Trauth N, et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nature Immunology. 2000;1(6):515-20.
43. Kobayashi H, Tanaka Y, Yagi J, Toma H, Uchiyama T. Gamma /delta T cells provide innate immunity against renal cell carcinoma. Cancer Immunology Immunotherapy. 2001;50(3):115-24.
44. Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH, Wang R. Tumor-infiltrating γδ T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity. 2007; 27(2):334-48.
45. Bilgi O, Karagoz B, Turken O, et al. Peripheral blood gamma-Delta T cells in advanced-stage cancer patients. Advances in Therapy. 2008;25(3): 218-24.
46. Yamasaki K, Horiguchi S, Kurosaki M, et al. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy. Clinical Immunology. 2010 Dec 23.
47. Berntsen A, Brimnes MK, Straten PT, Svane IM. Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and lowdose interleukin-2. Journal of Immunotherapy. 2010;33(4):425-34.
48. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of-tumor escape phenotypes. Nature Immunology. 2002;3(11):999-1105.
49. Luboldt H, Kubens B, Rubben H, Grosse-Wilde H. Selective loss of human leukocyte antigen class I allele expression in advanced renal cell carcinoma. Cancer Research. 1996;56:826-30.
50. De Smedt T, Van Mechelen M, De Becker G, Urbain J, Leo O, Moser M. Effect of interleukin-10 on dendritic cell maturation and function. European Journal of Immunology. 1997;27:1229-35.
51. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen- specific inhibition of effector T cell function in humans after injection of immature dendritic cells. The Journal of Experimental Medicine. 2001;193:233-8.